Phase I/II multicenter, randomized, open-label trial of the c-Met inhibitor MSC2156119J and gefitinib versus chemotherapy as second-line treatment in patients with MET-positive (MET plus ), locally advanced, or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor mutation (EGFRm plus ) and progression on gefitinib

被引：0
|
作者：
Wu, Yi-Long
Yang, James Chih-Hsin
Park, Keunchil
Xu, Lianzhe
Bladt, Friedhelm
Johne, Andreas
Li, Peiqi
Zheng, Hongxia
Massimini, Giorgio
机构：
[1] GGH, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
[3] Natl Taiwan Univ, Grad Inst Oncol, Taipei 10764, Taiwan
[4] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Innovat Canc Med Inst, Seoul, South Korea
[5] Merck Serono Pharmaceut R&D Co Ltd, Global Biostat, Beijing, Peoples R China
[6] Merck KGaA, Translat Innovat Platform Oncol, Global Res & Dev, Darmstadt, Germany
[7] Merck KGaA, Clin Pharmacol, Darmstadt, Germany
[8] Merck Serono Pharmaceut R&D Co Ltd, Global Clin Dev Ctr, Beijing, Peoples R China
[9] EMD Serono, Global Res & Early Dev, Boston, MA USA
[10] Merck KGaA, Global Res & Early Dev, Darmstadt, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.tps8121
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8121
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)
    Herbst, R. S.
    Sun, Y.
    Korfee, S.
    Germonpre, P.
    Saijo, N.
    Zhou, C.
    Wang, J.
    Langmuir, P.
    Kennedy, S. J.
    Johnson, B. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [22] The efficacy and safety of stereotactic body radiation therapy (SBRT) plus toripalimab with or without bevacizumab as second-line treatment for advanced non-small cell lung cancer (NSCLC): A prospective, multicenter, open-label, phase II study
    Sun, J.
    Xie, L.
    Feng, Y.
    Qin, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S1030 - S1030
  • [23] Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation-positive nonsquamous non-small cell lung cancer (NSCLC): An open-label randomized trial
    Kato, Terufumi
    Seto, Takashi
    Nishio, Makoto
    Goto, Koichi
    Atagi, Shinji
    Hosomi, Yukio
    Yamamoto, Noboru
    Hida, Toyoaki
    Maemondo, Makoto
    Nakagawa, Kazuhiko
    Nagase, Seisuke
    Okamoto, Isamu
    Yamanaka, Takeharu
    Harada, Ryosuke
    Fukuoka, Masahiro
    Yamamoto, Nobuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] A phase II study of gefitinib in combination with S-1 plus carboplatin as first-line chemotherapy for patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations
    Tamiya, Akihiro
    Tamiya, Motohiro
    Nakatani, Akeshi
    Shiroyama, Talcayuki
    Kitai, Kanako
    Tsuji, Taisuke
    Morishita, Naoko
    Omachi, Naold
    Asami, Kazuhiro
    Okamoto, Norio
    Suzuki, Hidekazu
    Okishio, Kyoichi
    Kawaguchi, Tomoya
    Hiroshima, Tomonort
    Atagi, Shinji
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [25] SI-B001 plus chemotherapy in patients with locally advanced or metastatic EGFR/ALK wild-type non-small cell lung cancer: A phase II, multicenter, open-label study
    Zhao, Yuanyuan
    Zhang, Li
    Fang, Wenfeng
    Yang, Yunpeng
    Huang, Yan
    Zou, Wen
    Wang, Zhaoxiang
    Ding, Muran
    Peng, Yujia
    Xiao, Sa
    Wang, Hongwei
    Zhu, Hai
    Olivo, Martin Sebastian
    Zhu, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] COST-EFFECTIVENESS ANALYSIS OF AFATINIB VERSUS GEFITINIB AS FIRST LINE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM
    Santoni, N. B.
    Melo, T. G.
    Aguirre, A. R.
    Veiga, D. L.
    Souza, C. P.
    VALUE IN HEALTH, 2017, 20 (05) : A106 - A106
  • [27] Phase III randomized, open label study (ARCHER 1050) of first-line dacomitinib (D) versus gefitinib (G) for advanced (adv) non-small cell lung cancer (NSCLC) in patients (pts) with epidermal growth factor receptor (EGFR) activating mutation(s).
    Mok, Tony
    Nakagawa, Kazuhiko
    Rosell, Rafael
    Wu, Yi Long
    Trygstad, Carl
    Capizzi, Robert L.
    Lee, Min Young
    Tsuji, Fumito
    DeBenedetto, Robert
    Goldberg, Zelanna
    Wang, Tao
    Liang, Jane Q.
    Letrent, Stephen P.
    O'Connell, Joseph P.
    Antic, Vladan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [28] Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer
    Wu, Yi-Long
    Zhang, Li
    Kim, Dong-Wan
    Liu, Xiaoqing
    Lee, Dae Ho
    Yang, James Chih-Hsin
    Ahn, Myung-Ju
    Vansteenkiste, Johan F.
    Su, Wu-Chou
    Felip, Enriqueta
    Chia, Vincent
    Glaser, Sabine
    Pultar, Philippe
    Zhao, Sylvia
    Peng, Bin
    Akimov, Mikhail
    Tan, Daniel S. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (31) : 3101 - +
  • [29] LUX-Lung 5: A Randomized, Open-Label, Phase III Trial of Afatinib (A) Plus Paclitaxel (P) Versus Investigator's Choice of Chemotherapy (ICC) in Patients (pts) With Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Had Progressed on Erlotinib/Gefitinib (E/G) and Afatinib
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2014, 12 (10) : 13 - 14
  • [30] A phase lb trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib
    Moran, Teresa
    Palmero, Ramon
    Provencio, Mariano
    Insa, Amelia
    Majem, Margarita
    Reguart, Noemi
    Bosch-Barrera, Joaquim
    Isla, Dolores
    Carcereny Costa, Enric
    Lee, Chooi
    Puig, Marta
    Kraemer, Sandrine
    Schnell, David
    Rosell, Rafael
    LUNG CANCER, 2017, 108 : 154 - 160
12345